


**WE CLAIM:**

1. A method for the treatment of a mammal infected with a virus of the *Flaviviridae* family comprising administering a therapeutically effective amount of a compound of Formula (I):



Formula (I)

wherein **A** is selected from: C<sub>1</sub> to C<sub>6</sub> alkyl and C<sub>3</sub> to C<sub>6</sub> cycloalkyl; **B** is selected from: phenyl or thiazolyl, both of which optionally substituted with a group selected from NH(R<sup>1</sup>) and NH(CO)R<sup>1</sup>, wherein R<sup>1</sup> is C<sub>1</sub> to C<sub>6</sub> alkyl; and **R** is OH or a sulfonamide group of the formula -NHSO<sub>2</sub>-R<sup>2</sup> wherein R<sup>2</sup> is -(C<sub>1-8</sub>)alkyl, -(C<sub>3-7</sub>)cycloalkyl or {-(C<sub>1-6</sub>)alkyl-(C<sub>3-6</sub>)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O-(C<sub>1-6</sub>)alkyl, amido, amino or phenyl, or R<sup>2</sup> is C<sub>6</sub> or C<sub>10</sub> aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C<sub>1-6</sub>)alkyl, O-(C<sub>1-6</sub>)alkyl, amido, amino or phenyl; or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein **A** of Formula (I) is a branched C<sub>4</sub> to C<sub>6</sub> alkyl or C<sub>4</sub> to C<sub>6</sub> cycloalkyl group, **B** of Formula (I) is phenyl or a thiazole substituted at position 2 with NH(R<sup>1</sup>) or NH(CO)R<sup>1</sup> in which R<sup>1</sup> is a C<sub>1</sub> to C<sub>4</sub> alkyl, and **R** is OH or a sulfonamide group of formula -NHSO<sub>2</sub>-R<sup>2</sup> wherein R<sup>2</sup> is -(C<sub>1-6</sub>)alkyl, -(C<sub>3-6</sub>)cycloalkyl, both optionally substituted 1 or 2 times with halo or phenyl, or R<sup>2</sup> is C<sub>6</sub> aryl optionally substituted from 1 or 2 times with halo or (C<sub>1-6</sub>)alkyl.
3. The method according to claim 2, wherein **A** is cyclopentyl or *tert*-butyl, **B** is a thiazole substituted at position 2 with NH(R<sup>1</sup>) or NH(CO)R<sup>1</sup> in which R<sup>1</sup> is a C<sub>1</sub> to C<sub>4</sub> alkyl, and **R** is OH or a sulfonamide group wherein R<sup>2</sup> is methyl, cyclopropyl or phenyl.

4. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is Yellow Fever virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with  $\text{NHCH}(\text{CH}_3)_2$ , and **R** is OH or a sulfonamide group wherein **R**<sup>2</sup> is methyl, cyclopropyl or phenyl.
5. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is West Nile virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with  $\text{NHCH}(\text{CH}_3)_2$ , and **R** is OH or a sulfonamide group wherein **R**<sup>2</sup> is methyl, cyclopropyl or phenyl.
6. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is Dengue fever virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with  $\text{NHCH}(\text{CH}_3)_2$ , and **R** is OH or a sulfonamide group wherein **R**<sup>2</sup> is methyl, cyclopropyl or phenyl.
7. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is Japanese Encephalitis virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with  $\text{NHCH}(\text{CH}_3)_2$ , and **R** is OH or a sulfonamide group wherein **R**<sup>2</sup> is methyl, cyclopropyl or phenyl.
8. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is GB virus A or C, and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with  $\text{NHCH}(\text{CH}_3)_2$ , and **R** is OH or a sulfonamide group wherein **R**<sup>2</sup> is methyl, cyclopropyl or phenyl.
9. The method according to claim 1, wherein said mammal is a human, said Flaviviridae is Hepatitis G virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with

NHCH(CH<sub>3</sub>)<sub>2</sub>, and **R** is OH or a sulfonamide group wherein **R**<sup>2</sup> is methyl, cyclopropyl or phenyl.

10. The method according to claim 1, wherein said mammal is a cattle, said Flaviviridae is BVDV and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with NHCH(CH<sub>3</sub>)<sub>2</sub>, and **R** is OH or a sulfonamide group wherein **R**<sup>2</sup> is methyl, cyclopropyl or phenyl.
11. The method according to claim 1, wherein said mammal is a sheep, said Flaviviridae is border disease virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with NHCH(CH<sub>3</sub>)<sub>2</sub>, and **R** is OH or a sulfonamide group wherein **R**<sup>2</sup> is methyl, cyclopropyl or phenyl.
12. The method according to claim 1, wherein said mammal is a pig, said Flaviviridae is Classical Swine Fever Virus and said compound is a compound of formula (I) wherein **A** is cyclopentyl, **B** is a thiazole substituted at its 2 position with NHCH(CH<sub>3</sub>)<sub>2</sub>, and **R** is OH or a sulfonamide group wherein **R**<sup>2</sup> is methyl, cyclopropyl or phenyl.
13. The method according to claim 1, wherein said Flaviviridae virus comprises an NS3 protease comprising amino acid residues selected from: H57, G137, S139, A156 and A157.
14. An article of manufacture comprising packaging material contained within which is a composition effective to inhibit a virus of the *Flaviviridae* family and the packaging material comprises a label which indicates that the composition can be used to treat infection by a virus of the *Flaviviridae* family and, wherein said composition comprises a compound of Formula (I) as defined in claim 1.